3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Mouth Neoplasms
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Recurrence
2
Mycosis Fungoides
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Vaccinia
1
Sinonasal Squamous Cell Carcinoma
1
Sarcoma
1
Resectable Non-small Cell Lung Cancer
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Immunoblastic Lymphadenopathy
1
Interventions
durvalumab
2
ruxolitinib
1
repotrectinib
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Docetaxel
1
Cisplatin
1
CPI-0610
1
Biopsy
1
Bevacizumab
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
cemiplimab
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled